ACAP2-IT1

Across TCGA pan-cancer cohorts, ACAP2-IT1 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ACAP2-IT1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ACAP2-IT1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ACAP2-IT1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LIHC, HNSC, and CHOL are the cancer types where ACAP2-IT1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACAP2-IT1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	II,III,IV	+0.193	<.001	8	view →
HNSC	All	All	+0.257	<.001	7	view →
CHOL	All	II,III,IV	+1.425	.005	4	view →
THCA	All	All	−0.275	.005	3	view →
LUSC	All	All	+0.445	<.001	2	view →
STAD	All	All	+0.382	.043	2	view →
KIRC	Male	All	+0.152	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ACAP2-IT1–LIHC

Open the LIHC breakdown →